Zika virus infection from a newborn point of view. TORCH or TORZiCH?
Author:
Tahotná Adriana1, Brucknerová Jana1, Brucknerová Ingrid2
Affiliation:
1. Faculty of Medicine Comenius , University in Bratislava , Slovakia 2. Neonatal Department of Intensive Medicine, Medical Faculty , Comenius University in Bratislava and National Institute of Children’s Diseases
Abstract
Abstract
Zika virus (ZIKV) belongs to the group of viruses called arboviruses. Congenital Zika syndrome is a new disease with infectious teratogenic aetiology. The clinical symptoms are divided into morphological and functional. Most severe complication is the foetal brain disruption sequence that includes severe microcephaly, anomalies of the eyes and congenital contractions of joints. The aim of this paper was to review available facts about Zika virus infection from a newborn point of view in a form of the summary of all important information. Zika virus infection is a problem of past, present and future. Epidemics may occur because of global climate changes, also in countries where natural conditions for life of mosquitos are not present. This clearly indicates the need to continue developing of vaccines and specific antiviral drugs. Until this happens, we must adhere individual preventive measures. Zika virus has proven to us how it can affect the health of adults and neonates but also thinking of healthy people. Newborns with microcephaly on the front pages of the media caused in 2015 panic and fear around the world – for this reason education of people is necessary. Due to serious congenital disorders associated with ZIKV infection and global impact of virus we suggest modifying old acronym TORCH for new TORZiCH to accent the position of Zika virus.
Publisher
Walter de Gruyter GmbH
Subject
Health, Toxicology and Mutagenesis,Pharmacology,Toxicology
Reference26 articles.
1. Besnard M, Lastère S, Teissier A, Cao-Lormeau VM, Musso D. (2014). Evidence of perinatal transmission of Zika virus, French Polynesia, December 2013 and February 2014. Euro Surveill19(13): pii: 20751. 2. Bollati M, Alvarez K, Assenberg R, Baronti C, Canard B, Cook S, Coutard B, Decroly E, de Lamballerie X, Gould EA, Grard G, Grimes JM, Hilgenfeld R, Jansson AM, Malet H, Mancini EJ, Mastrangelo E, Mattevi A, Milani M, Moureau G, Neyts J, Owens RJ, Ren J, Selisko B, Speroni S, Steuber H, Stuart DI, Unge T, Bolognesi M. (2010). Structure and functionality in flavivirus NS-proteins: Perspectives for drug design. Antiviral Res87(2): 125–14810.1016/j.antiviral.2009.11.009 3. Cao-Lormeau VM, Blake A, Mons S, Lastere S, Roche C, Vanhomwegen J, Dub T, Baudouin L, Teissier A, Larre P, Vial AL, Decam C, Choumet V, Halstead SK, Willison HJ, Musset L, Manuguerra JC, Despres P, Fournier E, Mallet HP, Musso D, Fontanet A, Neil J, Ghawché F. (2016). Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet387(10027): 1531–1539. 4. CDC. National Center for Emerging and Zoonotic Infectious Diseases (NCEZID). Division of Vector-Borne Diseases (DVBD). (2017). [cit. 2017-08-30]. https://www.cdc.gov/zika/hc-providers/infants-children/evaluation-testing.html#clinicianresources 5. Dick GWA, Kitchen SF, Haddowab AJ (1952) Zika virus (I). Isolations and sero-logical specificity. Trans R Soc Trop Med Hyg [online]. 46(5): 509–20.10.1016/0035-9203(52)90042-4
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|